CAR-T细胞治疗在自身免疫性疾病中的应用  

Application of CAR-T cell therapy in autoimmune diseases

作　　者：李春晖 李春蕊[1] LI Chun-hui;LI Chun-rui(Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院血液内科,湖北武汉430030

出　　处：《内科急危重症杂志》2023年第5期363-369,385,共8页Journal of Critical Care In Internal Medicine

基　　金：国家自然科学基金(No:82170223)。

摘　　要：嵌合抗原受体T(CAR-T)细胞疗法在血液肿瘤取得了令人瞩目的成绩,研究者尝试将该技术拓展用于系统性红斑狼疮、视神经脊髓炎、重症肌无力、1型糖尿病等自身免疫性疾病。本文概述了CAR-T、嵌合自身抗体受体T细胞(CAAR-T)和嵌合抗原受体调节T细胞(CAR-Treg)治疗自身免疫性疾病的病理基础及研究进展。Chimeric antigen receptor T(CAR-T)cell therapy has garnered remarkable achievements in the treatment of hematologic malignancies,prompting researchers to explore the application of CAR technology for refractory autoimmune disorders,including systemic lupus erythematosus,neuromyelitis optica,myasthenia gravis,type 1 diabetes,and so on.This article provides an overview of the pathological basis and recent advancements in utilizing CAR-T,chimeric autoantibody receptor T cells(CAAR-T),and CAR-T regulatory cells(CAR-Treg)for the treatment of autoimmune diseases.

关 键 词：嵌合抗原受体T细胞 嵌合自身抗体受体T细胞 嵌合抗原受体调节T细胞 自身免疫性疾病 

分 类 号：R593.2[医药卫生—内科学]